Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...

Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...

The Organoid group at the Hubrecht Institute have identified a new link between FBXW7 mutations and EGFR signaling activity. The FBXW7 gene is commonly mutated in colorectal cancer and such mutations ...

Second clinical candidate from HUTCHMED’s next-generation ATTC platform —— Leveraging synergy through simultaneous inhibition of PAM pathway ...

Co-occurring alterations in EGFR-mutant NSCLC are increasingly detected via broad NGS and may signal aggressive biology, prompting interest in escalation strategies that address concurrent drivers.

EGFR-positive lung cancer is more common in non-smokers (particularly those with adenocarcinoma) and younger adults, as it often develops from a single genetic mutation rather than widespread DNA ...